These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 35246262)

  • 1. Mutational status may supersede tumor size in predicting the presence of aggressive pathologic features in well differentiated thyroid cancer.
    Semsar-Kazerooni K; Morand GB; Payne AE; da Silva SD; Forest VI; Hier MP; Pusztaszeri MP; Tamilia M; Payne RJ
    J Otolaryngol Head Neck Surg; 2022 Mar; 51(1):9. PubMed ID: 35246262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm.
    Silver JA; Bogatchenko M; Pusztaszeri M; Forest VI; Hier MP; Yang JW; Tamilia M; Payne RJ
    J Otolaryngol Head Neck Surg; 2021 Nov; 50(1):63. PubMed ID: 34742355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mutations as a possible factor for determining extent of thyroid surgery.
    Krasner JR; Alyouha N; Pusztaszeri M; Forest VI; Hier MP; Avior G; Payne RJ
    J Otolaryngol Head Neck Surg; 2019 Oct; 48(1):51. PubMed ID: 31623671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased diagnostic sensitivity of palpation-guided thyroid nodule fine-needle aspiration cytology by BRAF V600E-mutation analysis.
    Gimm O; Ivansson K; Beka E; Rossitti HM; Garvin S; Söderkvist P
    J Pathol Clin Res; 2021 Nov; 7(6):556-564. PubMed ID: 34156770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF and RAS Mutational Status in Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features and Invasive Subtype of Encapsulated Follicular Variant of Papillary Thyroid Carcinoma in Korea.
    Kim M; Jeon MJ; Oh HS; Park S; Kim TY; Shong YK; Kim WB; Kim K; Kim WG; Song DE
    Thyroid; 2018 Apr; 28(4):504-510. PubMed ID: 29439609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma.
    An JH; Song KH; Kim SK; Park KS; Yoo YB; Yang JH; Hwang TS; Kim DL
    Clin Endocrinol (Oxf); 2015 May; 82(5):760-6. PubMed ID: 25109485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area.
    Lee ST; Kim SW; Ki CS; Jang JH; Shin JH; Oh YL; Kim JW; Chung JH
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2299-306. PubMed ID: 22500044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
    Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
    Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.
    Kim SJ; Lee KE; Myong JP; Park JH; Jeon YK; Min HS; Park SY; Jung KC; Koo do H; Youn YK
    World J Surg; 2012 Feb; 36(2):310-7. PubMed ID: 22190222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma.
    Givens DJ; Buchmann LO; Agarwal AM; Grimmer JF; Hunt JP
    Laryngoscope; 2014 Sep; 124(9):E389-93. PubMed ID: 24604709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors.
    Jung CK; Kim Y; Jeon S; Jo K; Lee S; Bae JS
    Hum Pathol; 2018 Nov; 81():9-17. PubMed ID: 29723601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between US-FNAC with BRAF V600E Mutation Analysis and Central Neck Lymph Node Metastasis in cN0 Papillary Thyroid Cancer.
    Li R; Hao J; Zhu Z; Qiao X; Wang L; Zhou Z
    Biomed Res Int; 2021; 2021():9937742. PubMed ID: 34307677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomorphologic features in thyroid nodules read as "suspicious for malignancy" on cytology may predict thyroid cancers with the BRAF mutation.
    Kwon HJ; Kim EK; Kwak JY
    Pathol Res Pract; 2015 Sep; 211(9):671-6. PubMed ID: 26187369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
    Huang M; Yan C; Xiao J; Wang T; Ling R
    Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Follicular variant of papillary thyroid cancer: encapsulated, nonencapsulated, and diffuse: distinct biologic and clinical entities.
    Gupta S; Ajise O; Dultz L; Wang B; Nonaka D; Ogilvie J; Heller KS; Patel KN
    Arch Otolaryngol Head Neck Surg; 2012 Mar; 138(3):227-33. PubMed ID: 22431868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular evaluation of BRAF gene mutation in thyroid tumors: Significant association with papillary tumors and extra thyroidal extension indicating its role as a biomarker of aggressive disease.
    Ahmad F; Nathani R; Venkat J; Bharda A; Vanere V; Bhatia S; Das BR
    Exp Mol Pathol; 2018 Dec; 105(3):380-386. PubMed ID: 30414980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How limited molecular testing can also offer diagnostic and prognostic evaluation of thyroid nodules processed with liquid-based cytology: Role of TERT promoter and BRAF V600E mutation analysis.
    Dell'Aquila M; Fiorentino V; Martini M; Capodimonti S; Cenci T; Lombardi CP; Raffaelli M; Pontecorvi A; Fadda G; Pantanowitz L; Larocca LM; Rossi ED
    Cancer Cytopathol; 2021 Oct; 129(10):819-829. PubMed ID: 34076961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The BRAF(V600E) mutation is associated with malignant ultrasonographic features in thyroid nodules.
    Lee EJ; Song KH; Kim DL; Jang YM; Hwang TS; Kim SK
    Clin Endocrinol (Oxf); 2011 Dec; 75(6):844-50. PubMed ID: 21707687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
    Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
    Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative RAS mutational analysis is of great value in predicting follicular variant of papillary thyroid carcinoma.
    Hwang TS; Kim WY; Han HS; Lim SD; Kim WS; Yoo YB; Park KS; Oh SY; Kim SK; Yang JH
    Biomed Res Int; 2015; 2015():697068. PubMed ID: 25648502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.